SCHEMBL771792

SCHEMBL771792

COC(=O)CCCS(=O)(=O)N1CCCC2CCCC=C21

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MMP8 P22894 1/20 0.34
MMP12 P39900 1/20 0.34
MMP13 P45452 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
SMYD3 Q9H7B4 1/20 0.32
OPRD1 P41143 2/20 0.32
ELOVL6 Q9H5J4 1/20 0.32
TSHR P16473 2/20 0.32
POLB P06746 1/20 0.32
HSD17B10 Q99714 1/20 0.32
EPHX2 P34913 1/20 0.32
LMNA P02545 1/20 0.32
OPRM1 P35372 1/20 0.32
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770345 0.93 SMYD3 (0.37) ALDH1A1MEN1KMT2AMMP8MMP12
SCHEMBL770852 0.85 FFAR4 (0.33) ALDH1A1HRH3
SCHEMBL770150 0.81 POLB (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL770148 0.81 POLB (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL771132 0.81 POLB (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL770874 0.81 NPC1 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL770324 0.80 HTT (0.32) ALDH1A1KMT2AMMP8MMP12MMP13
SCHEMBL770641 0.80 CHRM2 (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL772409 0.79 KMT2A (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL771713 0.79 PDE3B (0.39) ALDH1A1MEN1KMT2ATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885MEN1 827/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885MEN1 823/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.